From: Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study
CONT | DCM | ICM | |
---|---|---|---|
Number of samples | 5 | 5 | 5 |
Gender (female/male) | 3/2 | 2/3 | 4/1 |
Age (year) | 29 ± 9 | 39 ± 10 | 57 ± 11*# |
NYHA functional class III/IV, n | n.a. | 0/5 | 3/2 |
PAP, mmHg | n.a. | 31.6 ± 4.7 | 30.8 ± 5.6 |
PWP, mmHg | n.a. | 24 ± 4.3 | 21 ± 3.5 |
LVED, mm | n.a. | 68 ± 4 | 71 ± 4 |
LVSD, mm | n.a. | 63 ± 5 | 61 ± 8 |
PW, mm | n.a. | 9.5 ± 0.5 | 10 ± 1.5 |
IVS, mm | n.a. | 10 ± 0.7 | 11 ± 1.5 |
LVEF, % | n.a. | 16 ± 3 | 23 ± 3 |
Medications | |||
ACE-inhibitor | - | ++ | ++ |
β-Blocker | - | ++ | ++ |
Diuretics | - | ++ | ++ |
Digitalis | - | + | + |
PDE-inhibitor | - | ++ | ++ |
Dopamine/Noradrenaline | ++ | ++ | + |
Statin | - | - | ++ |
Aspirin | - | - | ++ |
Desmopressin | ++ | - | - |